A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state |
| |
Authors: | Patkar Ashwin Gilmer William Pae Chi-un Vöhringer Paul A Ziffra Michael Pirok Edward Mulligan Molly Filkowski Megan M Whitham Elizabeth A Holtzman Niki S Thommi Sairah B Logvinenko Tanya Loebel Antony Masand Prakash Ghaemi S Nassir |
| |
Affiliation: | Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, United States of America. |
| |
Abstract: | ObjectiveTo examine the efficacy of ziprasidone vs. placebo for the depressive mixed state in patients with bipolar disorder type II or major depressive disorder (MDD).Methods73 patients were randomized in a double-blinded, placebo-controlled study to ziprasidone (40-160 mg/d) or placebo for 6 weeks. They met DSM-IV criteria for a major depressive episode (MDE), while also meeting 2 or 3 (but not more nor less) DSM-IV manic criteria. They did not meet DSM-IV criteria for a mixed or manic episode. Baseline psychotropic drugs were continued unchanged. The primary endpoint measured was Montgomery- Åsberg Depression Rating Scale (MADRS) scores over time. The mean dose of ziprasidone was 129.7±45.3 mg/day and 126.1±47.1 mg/day for placebo.ResultsThe primary outcome analysis indicated efficacy of ziprasidone versus placebo (p = 0.0038). Efficacy was more pronounced in type II bipolar disorder than in MDD (p = 0.036). Overall ziprasidone was well tolerated, without notable worsening of weight or extrapyramidal symptoms.ConclusionsThere was a statistically significant benefit with ziprasidone versus placebo in this first RCT of any medication for the provisional diagnostic concept of the depressive mixed state.Trial RegistrationClinicaltrials.gov {"type":"clinical-trial","attrs":{"text":"NCT00490542","term_id":"NCT00490542"}}NCT00490542 |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|